Skip to main content Accessibility help

Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden

  • Ingrid Lekander (a1), Fredrik Borgström (a1), Patrick Svarvar (a2), Tryggve Ljung (a2), Cheryl Carli (a3) and Ronald F. van Vollenhoven (a3)...


Objectives: The objective of this study was to estimate the cost-effectiveness of infliximab use in patients with rheumatoid arthritis (RA) in Swedish clinical practice, based on patient-level data from the Stockholm TNF-alpha follow-up registry (STURE).

Methods: Real-world patient-level data on infliximab use from the STURE registry were implemented in a Markov cohort model, in which health states of functional status were classified according to the Health Assessment Questionnaire Disability Index (HAQ—five categories) and twenty-eight joint count Disease Activity Score (DAS28). The transition probabilities between HAQ and DAS28 states during treatment, as well as discontinuation rates were modeled based on data from the registry for patients using infliximab as their first-line biological treatment. The transition probabilities in the comparator arm, that is, disease progression without biologic treatment, as well as mortality rates, costs, and utilities were based on published literature. The analysis had a societal cost perspective.

Results: Infliximab was associated with an incremental gain in quality-adjusted life-years of 1.02 and an incremental cost of €23,264 per patient compared with progression without biologic treatment, producing an incremental cost-effectiveness ratio (ICER) of €22,830 (SEK211,136 or US$31,230). Sensitivity analyses of input parameters and model assumptions produced ICERs in the range from €18,000 to €47,000.

Conclusions: Results from base-case and sensitivity analyses fell well below established benchmarks for cost-effectiveness in Sweden. The results, therefore, indicated that infliximab treatment for RA has provided good societal value for money in Swedish clinical practice, compared with a scenario of no biological treatment.



Hide All
1. Askling, J. Risk for tuberculosis following treatment of rheumatoid arthritis with anti-TNF therapy—the Swedish experience 1998–2008. Ann Rheum Dis. 2009;68 (Suppl 3):422.
2. Askling, J, Fored, CM, Brandt, L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:19861992.
3. Askling, J, Fored, CM, Brandt, L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66:13391344.
4. Brennan, A, Bansback, N, Nixon, R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford). 2007;46:13451354.
5. Brennan, A, Bansback, N, Reynolds, A, Conway, P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford). 2004;43:6272.
6. Chehata, JC, Hassell, AB, Clarke, SA, et al. Mortality in rheumatoid arthritis: Relationship to single and composite measures of disease activity. Rheumatology (Oxford). 2001;40:447452.
7. Chen, YF, Jobanputra, P, Barton, P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10:1248.
8. Doan, QV, Chiou, CF, Dubois, RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12:555569.
9. Ekman, M, Zethraeus, N, Dahlstrom, U, Hoglund, C. [Cost-effectiveness of bisoprolol in chronic heart failure]. Lakartidningen. 2002;99:646650.
10. Geborek, P, Crnkic, M, Petersson, IF, Saxne, T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002;61:793798.
11. Jacobsson, LTH, Lindroth, Y, Marsal, L, Bergström, U, Kobelt, G. Rheumatoid arthritis: What does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmö, Sweden. Scand J Rheumatol. 2007;36:179183.
12. Katz, PP. The impact of rheumatoid arthritis on life activities. Arthritis Care Res. 1995;8:272278.
13. Kobelt, G, Jonsson, L, Young, A, Eberhardt, K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford). 2003;42:326335.
14. Kobelt, G, Lindgren, P, Lindroth, Y, Jacobson, L, Eberhardt, K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford). 2005;44:11691175.
15. Kobelt, G, Lindgren, P, Singh, A, Klareskog, L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis. 2005;64:11741179.
16. Kroot, EJ, van Leeuwen, MA, van Rijswijk, MH, et al. No increased mortality in patients with rheumatoid arthritis: Up to 10 years of follow up from disease onset. Ann Rheum Dis. 2000;59:954958.
17. Leden, IRS. Rapport från vårdprocess: Reumatologi dyr läkemedelsbehandling. 2003.
18. LFN Kostnadseffektiva läkemedel—LFN. (accessed September 25, 2008)
19. Lindqvist, E, Eberhardt, K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis. 1999;58:1114.
20. Meltzer, D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16:3364.
21. Pincus, T, Callahan, LF, Sale, WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864872.
22. Riise, T, Jacobsen, BK, Gran, JT, Haga, HJ, Arnesen, E. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol. 2001;20:123127.
23. Scott, DL, Pugner, K, Kaarela, K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford). 2000;39:122132.
24. Silman, A, Hochberg, M. Epidemiology of rheumatic diseases. 1993. Oxford: Oxford University Press.
25. Symmons, DP, Jones, MA, Scott, DL, Prior, P. Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well. J Rheumatol. 1998;25:10721077.
26. Yelin, E, Trupin, L, Wong, B, Rush, S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol. 2002;29:18511857.
27. Young, A, Dixey, J, Kulinskaya, E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis. 2002;61:335340.


Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden

  • Ingrid Lekander (a1), Fredrik Borgström (a1), Patrick Svarvar (a2), Tryggve Ljung (a2), Cheryl Carli (a3) and Ronald F. van Vollenhoven (a3)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed